BiOptix announces the launch of the BiOptix Innovators Program
BOULDER, Colo. and MOUNTAIN VIEW, Calif., Oct. 25, 2012 /PRNewswire/ -- BiOptix today announced the BiOptix Innovators Program, a pioneering instrument trial program that encourages researchers and institutions to become acquainted with the upcoming BiOptix 404pi, the first commercially available SPR instrument to incorporate phase-based common path interferometry technology.
BiOptix announced the new program while participating in Russian Innovation Week, held at the Computer History Museum in Mountain View, CA from October 25-26th 2012. Sponsored in part by Rusnano, the event brings together leading startup entrepreneurs, venture capitalists and successful business leaders from the U.S. and Russia to forge partnerships and pathways for doing business in Russia. Rusnano, who invested in BiOptix in 2011, led the Series B round of financing with Boulder Ventures and other private investors.
The BiOptix Innovators Program is a simple way for researchers to become acquainted with the BiOptix SPR platform. Depending on the needs of the customer, BiOptix invites qualified researchers to send in a molecular model of interest to test in our laboratory facilities on the new BiOptix 404pi or BiOptix can place an instrument—free of charge and with training—into a research facility for an on-site trial.
Surface Plasmon Resonance is an advanced and highly sensitive optical technology that can measure refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.
BiOptix Diagnostics Corporation is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures and Rusnano. BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at: www.bioptix.com